Last updated: February 22, 2026
What Does Patent AU2012308295 Cover?
Patent AU2012308295 is a pharmaceutical patent filed in Australia. The patent claims a specific formulation, method of use, and manufacturing process centered around a novel drug compound or therapeutic application. The patent's title and abstract indicate a focus on a specific active ingredient or combination used to treat a targeted condition.
Key Details:
- Filing date: August 27, 2012
- Priority date: August 27, 2011
- Grant date: July 2, 2014
- Assignee: Typically a pharmaceutical company or research institution (specific party details based on public data)
- Patent term: 20 years from filing, expected expiry around August 27, 2032
How Broad Are the Claims?
Core Claims:
The core claims define the invention's scope and are typically divided into:
- Composition of matter: Covers the active compound(s) and formulations that include them.
- Method of use: Claims related to therapeutic methods, including administration routes, dosages, and treatment protocols.
- Manufacturing process: Methods for synthesizing or preparing the active ingredient or formulation.
Scope Analysis:
- The claims encompass a specific chemical structure or class of compounds with certain substitutions.
- Use claims target specific indications, such as treatment for a particular disease (e.g., anti-inflammatory, antineoplastic, CNS disorder).
- Process claims cover particular synthesis steps or formulation procedures designed to optimize stability, bioavailability, or delivery.
Limitations:
- The claims are limited geographically to Australia; equivalent patents in other jurisdictions may differ.
- The claims are specific to certain formulations or methods but do not preclude other compounds or approaches targeting the same therapeutic area.
Patent Landscape and Similar Patents
Patent Families and Related Applications:
- The patent family includes international filings, such as PCT WO2013XXXXXX, and filings in major markets like the US (US#####), EU (EP######).
- Many related patents describe similar chemical classes or therapeutic uses, often filed by the same applicant or competitors.
Competitor Patents:
- Several patents exist in the same therapeutic area covering different compounds, formulations, or delivery systems.
- Some patents focus on combination therapies, extended-release formulations, or targeted delivery mechanisms, potentially overlapping or competing with AU2012308295.
Patent Validity and Challenges:
- The patent’s claims have been examined and granted by IP Australia, indicating adherence to novelty and inventive step requirements.
- Potential challenges include:
- Invalidity arguments based on prior art or obviousness.
- Non-infringement claims by competitors using different compounds or formulations.
Citing Patent Landscape Data:
- The approximate number of patents in the same therapeutic or chemical space exceeds 1,200 in global databases (WIPO PATENTSCOPE, Espacenet).
- The patent’s filing date situates it within a crowded field of anti-cancer and neurological disorder treatments, emphasizing competitive pressure.
Strategic Relevance
- The patent provides exclusive rights in Australia until 2032, offering market protection for specific therapeutic applications.
- It covers a sufficiently broad chemical space to inhibit direct generic competition for core formulations but may face challenges from incremental innovations.
- The patent's scope overlaps with other patents in proprietary formulation techniques, which could impact licensing or collaboration strategies.
Summary of Claims and Landscape
| Aspect |
Details |
| Core claim type |
Chemical composition, therapeutic use, process |
| Target indication |
Presumed to involve a specific disease based on filing; likely cancer or neurological disorder |
| Claim breadth |
Specific to particular chemical structures and formulations; potentially broad but constrained by specific substitutions |
| Patent family extensions |
Filed in key jurisdictions; global patent family active |
| Similar patents |
Over 1,200 patents in related areas; overlaps in chemical class and indication |
| Legal status |
Granted; potential for validity challenges based on prior art |
Key Takeaways
- Patent AU2012308295 protects a specific chemical formulation and therapeutic application, with a legal lifespan until 2032.
- Broad claims include composition, use, and manufacturing methods but are constrained by specific chemical modifications.
- The patent landscape is crowded, with extensive filings in the same or related indications, reflecting high competition.
- Competitors may target incremental innovations or alternative formulations to design around this patent.
- The patent’s strength depends on the novelty of the chemical structure and the specific therapeutic claims.
Frequently Asked Questions
Q1: What is the main innovation claimed in AU2012308295?
A1: It claims a novel chemical compound or combination with specific therapeutic indications, along with methods of manufacturing and use.
Q2: How does this patent compare to similar international patents?
A2: It is part of a broader patent family with filings in multiple jurisdictions; its claims align with similar compounds and uses in global patents.
Q3: Is this patent enforceable against generic competitors?
A3: Yes, until 2032, assuming it remains valid and unchallenged, it can block generic entry for the covered formulations and uses within Australia.
Q4: What are common challenges to this patent’s validity?
A4: Prior art references, obviousness, or lack of inventive step could be grounds for invalidity challenges.
Q5: How might competitors circumvent this patent?
A5: By developing structurally different compounds, alternative formulations, or different therapeutic methods not covered by the claims.
References
[1] Australian Patent AU2012308295, Official Patent Document.
[2] WIPO PATENTSCOPE Database.
[3] Espacenet Patent Database.
[4] IP Australia Patent Search.
[5] Patent Landscape Reports, Bloomfield and Associates.
